GMED (GMED)
Quantitative Summary
DeterministicFinancial health metrics are strong: Piotroski 8/9, Altman Z 10.9 (above 3.0 safe zone threshold).
Generated deterministically from quant metrics and financial statements. Not a recommendation.
Algorithmic Teardown
AI-GeneratedThe fundamental economics of GMED present a compelling profile characterized by exceptional profitability and robust financial health. A high gross margin of 67.4% combined with an net margin of 18.3% suggests strong pricing power or low cost structures, which directly supports the observed revenue growth rate of 16.7%. This operational efficiency is underpinned by a Piotroski F-Score of 8/9 and an Altman Z-Score of 10.9, indicating superior balance sheet strength and minimal distress risk relative to peers. Furthermore, the Beneish M-Score of -2.39 signals low likelihood of earnings manipulation, while an ROIC of 8.8% reflects efficient capital deployment, though its spread against a typical WACC would require external cost-of-capital assumptions not provided in this dataset.
Valuation metrics reveal that the current P/E ratio of 21.2x sits within a specific context relative to historical norms and sector averages, which are undefined in the available data but necessary for precise benchmarking. The DCF model implies a fair value of $155 per share; comparing this intrinsic estimate against the current market price is critical to determining whether the stock is trading at a premium or discount based on implied future growth assumptions. Without explicit historical P/E ranges or sector comparables, it remains unclear if the 21.2x multiple fully compensates for the company's high margin profile and double-digit revenue expansion.
The synthesis of these factors paints a picture of a financially resilient entity with strong earnings quality, yet the risk-reward equilibrium depends heavily on how the market prices its future growth trajectory versus current fundamentals. The absence of specific sector data limits the ability to contextualize the 16.7% growth rate or determine if the valuation is historically expansive for this industry segment. Investors must weigh the certainty provided by high F-Scores and low manipulation scores against the unknowns regarding competitive positioning within an unidentified sector when assessing potential downside protection versus upside participation.
Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.
DCF Sandbox
InteractiveSensitivity Matrix
| TG ↓ / WACC → | 8% | 10% | 12% |
|---|---|---|---|
| 2% | $189 | $139 | $110 |
| 3% | $221 | $155 | $119 |
| 4% | $269 | $177 | $131 |
Center = base case. Green = >10% upside, Red = >10% downside vs —.
Pre-computed DCF: WACC=10.0%, terminal growth 3%. Fair value $155 (+0.0%). Not investment advice.
Price Chart with Moving Averages
Quant Health Deep Dive
Profitability & Value Creation
Balance Sheet Health
Earnings Surprise History
EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.
Underwater (Drawdown from Peak)
How far below the all-time high the price has been over time. Deeper = more pain for holders.
Rolling 60-Day Beta vs S&P 500 (VOO)
How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.
Fundamentals
Passive Flow Attribution
ETF Draft EffectWhen investors buy or sell ETFs like XHE or MDYG, the fund manager is mechanically forced to buy or sell GMED shares regardless of GMED's individual fundamentals. We estimate $606M of passive capital is structurally linked to GMED through 8 tracked ETFs. Passive flows have a limited but growing influence on GMED's daily trading dynamics.
Passive exposure = Σ (ETF AUM × stock weight in ETF) across 8 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.
ETF Contagion Visualizer
Simulate a price drop in GMED to visualize passive redemption contagion across ETFs and collateral stocks.
If GMED (GMED) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies FLEX LTD (FLEX) as the most exposed collateral stock, sharing 2 ETFs with GMED. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.
Contagion model based on shared ETF exposure and constituent weights across 13 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.
GMED Ownership Dynamics
ETFs with Highest GMED Exposure
Float lock-up computed from 13 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).
GMED Capital Efficiency
How efficiently does GMED convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.
GMED converts 71% of its EBITDA into free cash flow, an exceptional conversion rate indicating an asset-light business model with minimal capital reinvestment drag.
Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.
Fails-to-Deliver (FTD) History
SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.
| Date | Failed Shares | Close Price | Notional Value |
|---|---|---|---|
| 2026-05-06 | 1 | $90.03 | $90.03 |
| 2026-04-16 | 11,109 | $94.55 | $1.1M |
| 2026-04-06 | 243 | $87.92 | $21,364.56 |
| 2026-03-27 | 19 | $86.50 | $1,643.5 |
| 2026-03-23 | 54 | $86.26 | $4,658.04 |
| 2026-02-23 | 663 | $90.59 | $60,061.17 |
| 2026-02-09 | 996 | $87.81 | $87,458.76 |
| 2026-01-27 | 7,721 | $92.98 | $717,898.58 |
| 2026-01-22 | 1,608 | $94.15 | $151,393.2 |
| 2026-01-21 | 26,643 | $92.95 | $2.5M |
| 2026-01-15 | 640 | $92.46 | $59,174.4 |
| 2025-12-22 | 4,965 | $87.06 | $432,252.9 |
| 2025-12-19 | 2,927 | $86.88 | $254,297.76 |
| 2025-12-18 | 455 | $85.06 | $38,702.3 |
| 2025-12-12 | 298 | $88.88 | $26,486.24 |
| 2025-12-03 | 304 | $89.03 | $27,065.12 |
| 2025-12-02 | 301 | $89.79 | $27,026.79 |
| 2025-12-01 | 301 | $91.04 | $27,403.04 |
| 2025-11-24 | 23 | $86.02 | $1,978.46 |
| 2025-11-07 | 278 | $61.71 | $17,155.38 |
Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.
Compare GMED to Peers
Quant metrics computed deterministically from financial statements and price data. Updated: N/A.
SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.